Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2017

Open Access 01-04-2017 | Original Article

68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

Authors: Mike Sathekge, Thabo Lengana, Moshe Modiselle, Mariza Vorster, JanRijn Zeevaart, Alex Maes, Thomas Ebenhan, Christophe Van de Wiele

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2017

Login to get access

Abstract

Background

To report on imaging findings using 68Ga-PSMA-HBED-CC PET in a series of 19 breast carcinoma patients.

Methods

68Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status.

Results

Out of 81 tumor lesions identified, 84% were identified on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptor-negative lesions. SUV values derived from FDG PET/CT, available in seven patients, and 68Ga-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p = 0.015).

Conclusions

68Ga-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry.
Literature
1.
O’Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, et al. Mapping, genomic organization and promotor analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta. 1998;1443(1-2):113–27.CrossRefPubMed
2.
Maurer T, Eiber M, Schwaiger M, Gschwend J. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226–35.CrossRefPubMed
3.
Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, et al. New clinical indications for 18F/11C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol. 2016;70(1):161–75.CrossRefPubMed
4.
Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, et al. Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016;57(4):563–7.CrossRefPubMed
5.
Chang S, Reuter V, Heston W, Bander N, Grauer L, Gaudin P. Five different anti-prostate-specific membrane antigen (PSMA) antibodies conform PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192–8.PubMed
6.
Sathekge M, Modiselle M, Vorster M, Mokgoro N, Nyakale N, Mokaleng B, et al. 68Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2015;42(9):1482–3.CrossRefPubMed
7.
Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KS, Liu H, et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS. 2014;122(6):482–9.CrossRefPubMed
8.
9.
Ebenhan T, Vorster M, Marjanovic-Painter B, Wagener J, Suthiram J, Modiselle M, et al. Development of a single vial kit solution for radiolabeling of 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients. Molecules. 2015;20(8):14860–78.
10.
Conway R, Petrovic N, Li Z, Heston W, Wu D, Shapiro L. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signaling transduction. Mol Cell Biol. 2006;26(14):5310–24.CrossRefPubMedPubMedCentral
11.
Grant CL, Caromile LA, Ho V, Durrani K, Rahman MM, Claffey KP, et al. Prostate-specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS One. 2012;7(7):e41285–9.CrossRefPubMedPubMedCentral
12.
Tsui P, Rubenstein M, Guinan P. Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. J Biomed Biotechnol. 2005;2005(3):287–90.CrossRefPubMedPubMedCentral
13.
Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50(2):277–89.CrossRefPubMed
14.
Vamesu S. Angiogenesis and progesterone receptor status in primary breast cancer patients: an analysis of 158 needle core biopsies. Rom J Morphol Embryol. 2007;48(3):267–74.PubMed
15.
Gebhart G, Flamen P, De Vries EG, Jhaveri K, Wimana Z. Imaging diagnostic and therapeutic targets: human epidermal growth factor receptor 2. J Nucl Med. 2016;57 Suppl 1:81S–8.CrossRefPubMed
16.
Podoloff DA, Advani RH, Allred C, Benson 3rd AB, Brown E, Burstein HJ, et al. NCCN task force report: positronemission tomography/computed tomography scanning in cancer. J Natl Compr Canc Netw. 2007;5 Suppl 1:S1–22.PubMed
17.
Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27 suppl 1:S215–29.CrossRefPubMed
18.
Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, et al. 18F-FDG PET and biomarkers for tumor angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(1):46–52.CrossRefPubMed
19.
Bos R, van der Hoeven JJ, van der Wall E, van der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20(2):379–87.CrossRefPubMed
20.
Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42(1):9–16.PubMed
21.
Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540–7.CrossRefPubMed
22.
Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57(9):1334–8.CrossRefPubMed
23.
Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin Cancer Res. 2016;22(13):3157–63.CrossRef
24.
25.
Wilson PM, LaBonte MJ, Lenz HJ. Assessing the in vivo efficacy of biologic antiangiogenic therapies. Cancer Chemother Pharmacol. 2013;71(1):1–12.CrossRefPubMed
26.
Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A. 1996;93(18):9764–9.CrossRefPubMedPubMedCentral
27.
Metadata
Title
68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
Authors
Mike Sathekge
Thabo Lengana
Moshe Modiselle
Mariza Vorster
JanRijn Zeevaart
Alex Maes
Thomas Ebenhan
Christophe Van de Wiele
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3563-6

Other articles of this Issue 4/2017

European Journal of Nuclear Medicine and Molecular Imaging 4/2017 Go to the issue

Reply

Reply by L. Maffioli

Original Article

Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor

Image of the Month

Diffuse 18F-FDG accumulation in the subarachnoid space detected by PET/CT in a patient with subarachnoid hemorrhage and hyperglycemia

Original Article

The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia

Original Article

Correlation of pretreatment 18F-FDG PET tumor textural features with gene expression in pharyngeal cancer and implications for radiotherapy-based treatment outcomes

Original Article

The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer